Gliadel Wafer Therapy
Fellowship-trained brain tumor surgeons • 12 hospital affiliations across New JerseyGliadel wafer (carmustine, or BCNU, impregnated biodegradable polymer wafer) is an FDA-approved local chemotherapy treatment placed directly into the tumor resection cavity at the time of brain tumor surgery. Up to eight wafers line the walls of the cavity after tumor removal, slowly releasing BCNU chemotherapy into the surrounding brain tissue over approximately 2 to 3 weeks delivering high local drug concentration directly to the area of highest tumor recurrence risk without the systemic side effects of intravenous chemotherapy.
Key takeaways
- Gliadel wafers are placed directly into the resection cavity during surgery, providing sustained local chemotherapy to the tissue most likely to harbor residual tumor cells.
- Up to eight biodegradable wafers gradually dissolve over approximately 2 to 3 weeks, releasing carmustine (BCNU) directly into the surrounding brain tissue.
- Gliadel is FDA-approved for newly diagnosed high-grade glioma and recurrent glioblastoma as an adjunct to surgical resection in appropriately selected patients.
- Clinical trials have demonstrated a modest but statistically significant survival benefit when Gliadel is added to standard surgical treatment.
- Treatment decisions are made collaboratively with the multidisciplinary neuro-oncology team at the Gerald J. Glasser Brain Tumor Center to determine whether Gliadel should be incorporated into an individual patient's treatment plan.
| Drug | Carmustine (BCNU) an alkylating chemotherapy agent |
| Delivery | Up to 8 biodegradable polymer wafers placed in tumor cavity at surgery |
| Release | Sustained local BCNU release over approximately 2 to 3 weeks |
| FDA approval | Newly diagnosed high-grade glioma and recurrent GBM |
| Placement | At the time of craniotomy and tumor resection no additional procedure |
| Used alongside | Radiation therapy and temozolomide chemotherapy (Stupp protocol) |
| Benefit | Modest survival improvement vs. surgery alone in randomized trials |
Timing and stay vary by patient and complexity. Your surgeon will confirm what to expect in your case.
Why local chemotherapy delivery matters in GBM
Glioblastoma almost invariably recurs at the margin of the original resection cavity the area of brain tissue immediately surrounding where the tumor was removed. This is because microscopic tumor cells infiltrate beyond the visible tumor margins into apparently normal brain tissue. These cells survive surgery and are the source of recurrence.
Systemic chemotherapy (oral or IV) must cross the blood-brain barrier to reach these cells, limiting the concentration that can be achieved in brain tissue. Gliadel wafers bypass the blood-brain barrier by delivering BCNU directly into the resection cavity, creating drug concentrations in the surrounding tissue that are orders of magnitude higher than those achievable with systemic chemotherapy.
The tradeoff is that the drug is concentrated at the cavity margin and does not reach distant tumor cells beyond the immediate surrounding brain tissue. For this reason, Gliadel is used as a local adjunct to systemic treatment not a replacement for it.
Integration with the GBM treatment plan
Gliadel wafer placement is planned before surgery and coordinated with the patient’s overall treatment strategy. Atlantic Brain and Spine’s fellowship-trained brain tumor neurosurgeons work closely with the multidisciplinary neuro-oncology team at the Gerald J. Glasser Brain Tumor Center to determine whether Gliadel is appropriate based on:
- Extent of planned resection — Gliadel is most beneficial after gross total or near-total resection when the resection cavity is well defined.
- Patient-specific factors — Wound healing, infection risk, prior radiation therapy, and overall treatment goals are considered.
- Integration with postoperative therapy — Temozolomide, radiation therapy, Tumor Treating Fields (TTFields), molecular tumor characteristics, and eligibility for clinical trials are incorporated into the overall treatment plan.
After surgery, patients continue multidisciplinary care with the neuro-oncology and radiation oncology teams. Standard chemoradiation typically begins 4 to 6 weeks after surgery once healing is complete. The Gliadel wafers gradually biodegrade and do not interfere with postoperative MRI interpretation or radiation treatment planning.
Benefits and risks
Potential benefits
- Delivers high-concentration chemotherapy directly to the area of highest GBM recurrence risk
- No additional procedure wafers are placed at the time of standard tumor resection
- No systemic chemotherapy toxicity from the Gliadel itself drug is localized to the cavity
- FDA-approved; established clinical evidence base with published randomized controlled trial data
Possible risks
- Increased risk of wound healing complications and CSF leak at the craniotomy site the local BCNU can impair tissue healing
- Brain swelling and edema around the cavity managed with steroids post-operatively
- Infection risk slightly elevated with foreign material in the cavity
- Seizure risk in the early post-operative period from local tissue reaction
Your surgeon will review the benefits and risks specific to your diagnosis during your consultation.
What recovery looks like
Recovery after brain tumor surgery with Gliadel wafer placement generally follows the same timeline as recovery after craniotomy alone, with some additional monitoring for local treatment-related effects.
- Days 1 to 3 Standard post-operative craniotomy recovery. Steroids may be adjusted to help manage local swelling related to surgery or Gliadel treatment. A post-operative MRI is typically obtained before discharge.
- Weeks 1 to 4 Incision healing is monitored closely. Any signs of wound breakdown, cerebrospinal fluid (CSF) leak, or infection are evaluated promptly while the Gliadel wafers gradually biodegrade.
- Weeks 4 to 6 Follow-up with neurosurgery, neuro-oncology, and radiation oncology. If appropriate, chemoradiation is initiated once healing is complete.
- Ongoing Continued MRI surveillance and multidisciplinary follow-up are tailored to the tumor type, pathology, molecular profile, and overall treatment plan.
Frequently asked questions
Do Gliadel wafers need to be removed?
No. The wafers are made from a biodegradable polymer (PCPP-SA) that fully breaks down in the body over 2 to 3 weeks, releasing the BCNU as they dissolve. Nothing remains to be removed.
Can Gliadel be used for recurrent GBM?
Yes. Gliadel is FDA-approved for recurrent GBM at re-operation. For patients who undergo repeat surgery for recurrent tumor, placement of Gliadel wafers provides a local chemotherapy adjunct at the second resection.
Does Gliadel replace temozolomide?
No. Gliadel and temozolomide work through different mechanisms and at different scales — Gliadel is a local treatment confined to the cavity margin, while temozolomide is a systemic treatment that reaches tumor cells throughout the brain. They are complementary, not interchangeable.
Will Gliadel wafers show up on MRI?
The wafers themselves are not consistently visible on MRI after placement. Local tissue changes from the BCNU release (edema, enhancement) may be visible on post-operative imaging and can sometimes be difficult to distinguish from early tumor recurrence a known interpretive challenge in GBM surveillance MRI that the neuro-oncology team is experienced in evaluating.
Brain Tumor Surgery Specialists at Atlantic Brain and Spine
Your care is provided by Atlantic Brain and Spine's multidisciplinary brain tumor team, including fellowship-trained brain tumor neurosurgeons who collaborate closely with the neuro-oncology team at the Gerald J. Glasser Brain Tumor Center.
